Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
HROW · against 589 other Healthcare companies listed in US-listed
Ranked #314 of 590 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including HROW · Click a bar to see the companies
Mainly because of its earnings yield and EBITDA yield, which are weaker than most Healthcare peers.
| Metric | HROW | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -3.8% | -4.4% | 51% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 1.5% | -0.8% | 56% | 50% | |
| Free cash flow yieldHigher is better · 554 reported | -1.3% | -2.3% | 54% | 20% | |
| Book yieldHigher is better · 587 reported | 1.6% | 26.6% | 12% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 253M USD | 98 | 80 | |
| 2 | 2.2B USD | 97 | 97 | |
| 3 | 563M USD | 96 | 97 | |
| 3 | 408M USD | 96 | 81 | |
| 3 | 322M USD | 96 | 57 | |
| 314 | 5.3B USD | 8 | 45 | |
| 314 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 425M USD |
| 8 |
| 21 |
| 314 | 613M USD | 8 |
| 314 | 5.6B USD | 8 | 30 |
| 314 | 976M USD | 8 | 32 |
| 314 | 4.5B USD | 8 | 46 |
| 314 | 8.5B USD | 8 | 31 |
| 314 | 3.0B USD | 8 | 54 |
| 314 | 201M USD | 8 | 41 |